SCHEMBL6790620

SCHEMBL6790620

CC1(C(O)c2ccc(-c3ccc(Cl)cc3)cc2)NC(=O)NC1=O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.43
MMP9 P14780 2/20 0.43
MMP8 P22894 2/20 0.43
BRD4 O60885 1/20 0.39
MMP13 P45452 3/20 0.39
RECQL P46063 1/20 0.38
ADAMTS5 Q9UNA0 3/20 0.36
ADAMTS4 O75173 1/20 0.36
MMP3 P08254 1/20 0.36
MMP12 P39900 1/20 0.36
AKR1B1 P15121 5/20 0.35
AKR1A1 P14550 1/20 0.35
HSD11B1 P28845 1/20 0.34
ADAM17 P78536 1/20 0.34
FFAR1 O14842 1/20 0.34
PGR P06401 1/20 0.34
PRCP P42785 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6791227 0.87 MMP2 (0.41) MMP2MMP9MMP8MMP3AKR1B1
SCHEMBL6789361 0.87 MMP2 (0.41) MMP2MMP9MMP8MMP3AKR1B1
SCHEMBL6791153 0.87 MMP2 (0.41) MMP2MMP9MMP8MMP3AKR1B1
SCHEMBL6795148 0.85 AKR1B1 (0.35) ADAMTS5AKR1B1AKR1A1HSD11B1FFAR1
SCHEMBL6798425 0.84 CYP17A1 (0.37) MMP13MMP12ADAM17
SCHEMBL6789612 0.83 PGR (0.36) MMP2MMP8MMP13ADAMTS5ADAM17
SCHEMBL6793983 0.83 MMP2 (0.45) MMP2MMP9MMP8MMP13FFAR1
SCHEMBL6791811 0.83 TYR (0.38) MMP2MMP9MMP13MMP3
SCHEMBL6793526 0.83 CA12 (0.40) MMP2MMP9MMP8
SCHEMBL6792387 0.83 MMP2 (0.45) MMP2MMP9MMP8MMP13MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 MMP2 2/4885MMP9 1/4885MMP8 19/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 MMP2 11/4885MMP9 8/4885MMP8 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.